Seminar on Diagnosis and Treatment of COVID-19
Project Overview

Project name	Seminar on Diagnosis and Treatment of COVID-19		
Organized by	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.		
Date	13 -16, September 2022	Language used	English
Countries invited	The Belt and Road countries	Planned participants	50
Training objectives	Through the training project, participants will systematically approach the diagnosis and treatment experience of COVID-19 in China, including the *COVID-19 Diagnosis and Treatment Scheme (Trial Version 9)*, the *Nursing Practice for Severe and Critical COVID-19 Patients*, the *Expert Consensus on Specimen Collection Technology for COVID-19 Patients*, the *Guidelines for Organization and Implementation of Regional COVID-19 Nucleic Acid Testing (Third Edition)*, etc. issued by the National Health Commission. Participants will learn innovative diagnosis and treatment methods for patients with COVID-19 variants and critical patients; and discuss the effective management mode of COVID-19 under the background of "combination of peacetime and wartime measures" of the global COVID-19, which would be able to help optimize the management mode of COVID-19 in the participating countries and improve the level of clinical diagnosis and treatment.		
Requirements for participants	Professional background	- Field or specialty: public health management, large medical institutions (infectious disease department, PCCM, etc.) - Post: healthcare supervisor, CDC staff, management and medical staff of large medical institutions, and university researchers - Professional level, educational background, or other qualification requirements: Ministers and directors of departments/divisions or above - Years of working in related fields: Professional ability and relevant working experience	
	Language competence	Fluent in English listening, speaking, reading, and writing	
	Others	1. The participating countries shall have good network conditions enabling participation in the online training smoothly. 2. Participants shall be able to arrange time to complete the whole seminar program reasonably. 3. Not higher than the legal retirement age of the participating country 4.This seminar will be held through the "LEARNIN" online teaching platform and Classin App as live-broadcasting platform	
Training overview	**1. Main training courses and description** **(1) General course** 1) An introduction to national conditions - China's basic political and economic systems, diplomatic ideas and development models will be introduced to enhance the understanding of		

China's national conditions.

2) Prevention and control of COVID-19 - The prevention and control strategies and international cooperation on COVID-19 in China will be presented, and the effective experience in COVID-19 prevention and control will be discussed.

(2) Specialized course:

1) Basic information on COVID-19:

① Etiological and epidemiological characteristics of COVID-19 (source of infection, susceptible population and route of transmission);

② Pathologic changes caused by COVID-19 (lung, spleen, lymph node and marrow, heart and blood vessel, liver and gallbladder, kidney and other organs);

③ Clinical characteristics of COVID-19 (clinical manifestation and laboratory examination).

2) Diagnosis and treatment of COVID-19:

① Diagnosis and clinical classification of COVID-19, and early warning of severe/critical patients (diagnosis principle and diagnosis criteria);

② Treatment of COVID-19 (isolation management and treatment sites shall be determined according to the condition, including general treatment, antiviral treatment, immunological treatment, anticoagulant treatment, prone position treatment, traditional Chinese medicine treatment and psychological intervention);

③ Traditional Chinese medicine treatment of COVID-19;

④ Supportive treatment of severe and critical COVID-19 patients (treatment principles, respiratory support, circulatory support, acute renal injury and renal replacement therapy, MIS-C, pregnant patients with severe or critical conditions and nutrition support);

⑤ Management of complications of COVID-19 (acute myocardial injury, acute gastroenteritis and acute liver injury, acute encephalitis, lymphopenia and DIC, acute renal injury, infection of pregnant woman, rhabdomyolysis, malnutrition, fever, psychological abnormality and impaired respiratory function).

3) Prevention and control of COVID-19:

① COVID-19 patient specimen collection technology (organization and implementation of COVID-19 nucleic acid testing);

② Comprehensive management of COVID-19 (case discovery and report, transfer, release of isolation, discharge standard, release of isolation management, discharge, etc.);

③ Infection prevention and control in medical institutions (personal protection for posts in different areas of medical institutions);

④ Prevention of COVID-19 (general prevention measures, vaccination, vaccination of COVID-19 vaccine for pregnant women, etc.).

(3) Discussion and exchange activities:

① Workshop on "diagnosis and treatment of COVID-19": Through this workshop, the effective experience, common difficulties and future challenges in the diagnosis and treatment of COVID-19 in various countries will be shared and discussed, especially the innovative treatment methods for the infection of Omicron specific strain and critical patients.

Workshop on "prevention and control of COVID-19": the effective management mode of

	COVID-19 under the background of "combination of peacetime and wartime measures" of the global COVID-19 will be exchanged and discussed.
	
	2. Introduction to Agencies and institutions of instructors
	1) The following agencies and institutions plan to send instructors for this seminar:
	  ① National Health Commission of the People's Republic of China
	  ② National (provincial) centers for disease control and prevention
	  ③ Chinese Medical Association
	  ④ Chinese Hospital Association
	  ⑤ School of Pharmacy of Fudan University, Fudan School of Public Health and other research institutions
	  ⑥ Key departments such as the infection department and PCCM of China's leading comprehensive public Grade A tertiary hospitals
	
	3. Materials required for participants to prepare
	    Participants shall participate in the discussion actively. Two participant representatives will be invited to introduce the diagnosis and treatment of COVID-19 in their own countries at the workshop on "diagnosis and treatment of COVID-19".
	
	4. Completion test/evaluation
	    Participants who go online on time for daily study and achieve more than 80% attendance rate without inferior performance, will be granted a completion certificate of foreign aid training of the Chinese government.

Remarks	1. Some instructors can teach directly in English, and the remaining courses are provided with simultaneous or consecutive interpreters of English. 2. This seminar will use the "LEARNIN" online teaching platform. The participants are required to contact the organizer at least 3 working days before the opening of the seminar for the account and user manual of the "LEARNIN" platform, install "Classin live" broadcast software, and timely test the online status. 3. During the process, participants are required to strictly abide by the project schedule (curriculum in the "LEARNIN" platform); Participants are required to enter the "Classin" live broadcast classroom through the platform 10 minutes before each class, and inform the assistant one day in advance if attendance is not available. 4. Participants are required to prepare relevant materials for the thematic seminar according to the schedule, and actively participate in the class communication and discussion.
About the organizer	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"). Founded in 1994, Fosun Pharma is driven by innovation and internationalization. Its business covers the whole medical and health industry chain, including pharmaceutical manufacturing and R&D, medical service, medical device and medical diagnosis, pharmaceutical distribution and retail. In 2021, it achieved the operation revenues of RMB 39.005 billion, including 34.86% of revenues from countries and regions outside mainland China, and has grown into a leading and global innovation-driven pharmaceutical and health industry group in China. Fosun Pharma adheres to innovative research and development, builds and forms small molecule innovative drug, antibody drug and cell therapy technology platforms around key disease areas such as tumor and immune regulation, four highs (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and complications as well as central nervous system, and

	actively explores cutting-edge technology fields such as targeted protein degradation, RNA, oncolytic virus and gene therapy. With its long-term innovative development in medicine and health, Fosun Pharma has established good cooperative relations with a large number of large public Grade A tertiary hospitals and medical experts with professional authority and a highly international perspective. It also has a wide distribution in the fields of COVID-19 vaccine, medicine, etc. Since 2007, supported and guided by Ministry of Commerce of the People's Republic of China and National Medical Products Administration, Fosun Pharma has successively undertaken 11 sessions of "Malaria Prevention and Control Seminar for Asian and African Countries" and 11 sessions of "Medicine Quality Management Seminar for Developing Countries". So far, it has provided training for 735 medical and health system participants from more than 60 countries. From 2015 to 2019, Fosun Pharma held four consecutive "Ministerial Workshop on Pharmaceutical Supervision and Management for Developing Countries" and enrolled a total of more than 20 ministerial medical and health officials to participate in the workshop.	
Contact information of the organizer	Project contact	Loren Liu
	Office Tel.	
	Mobile (recommended)	0086-13611780259
	Fax	
	WeChat Account	angel_4450V
	E-mail	liuyy@fosunpharma.com